

F Deangelis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7101000/publications.pdf>

Version: 2024-02-01

18
papers

1,028
citations

840776

11
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

2048
citing authors

#	ARTICLE	IF	CITATIONS
1	Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique. <i>NeuroImage: Clinical</i> , 2022, 33, 102904.	2.7	5
2	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	31
3	MS-SMART study: systematic sampling bias concerns – Authors' reply. <i>Lancet Neurology</i> , The, 2020, 19, 479-480.	10.2	0
4	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 2209-2218.	2.4	10
5	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	10.2	81
6	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.7	11
7	Fast bound pool fraction mapping via steady-state magnetization transfer saturation using single-shot EPI. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 1025-1040.	3.0	8
8	Novel Multiple Sclerosis Drugs in the Pipeline. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1082-1090.	4.7	3
9	Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 153.	2.4	13
10	New MS diagnostic criteria in practice. <i>Practical Neurology</i> , 2019, 19, 64-67.	1.1	4
11	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. <i>Neurology</i> , 2018, 90, e1183-e1190.	1.1	71
12	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 210-222.	5.3	295
13	Disease-modifying therapies for multiple sclerosis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4674.	2.3	76
14	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	1.9	43
15	Progression of regional grey matter atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 1665-1677.	7.6	269
16	Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. <i>CNS Drugs</i> , 2018, 32, 499-526.	5.9	18
17	Secondary Progressive Multiple Sclerosis: Definition and Measurement. <i>CNS Drugs</i> , 2016, 30, 517-526.	5.9	34
18	Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg : Application to multiple sclerosis. <i>NeuroImage: Clinical</i> , 2016, 10, 71-77.	2.7	56